ReWalk Robotics Reports Fourth Quarter

ReWalk Robotics Reports Fourth Quarter

2018 Financial Results

- 2018 total revenue of $6.5 million and $1.6 million during the fourth quarter of 2018 -

- Preparing for 2019 commercial launch of ReStore for stroke patients -

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, February 8, 2019

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company") today announced its financial

results for the three- and twelve-months ended December 31, 2018.

Highlights of and subsequent to the fourth quarter of 2018

"We believe that 2019 is poised to be a significant year

for ReWalk. I am excited by the momentum we are seeing in Europe for our SCI devices and the opportunity before us as we prepare

to launch our second product, the ReStore for stroke patients. We plan to enter the stroke market with a unique lightweight product

that fits into the existing reimbursement landscape, offering multiple treatment benefits for patients and a meaningful value proposition

for clinics. We are excited to bring this ground-breaking technology to market and believe its unique value will support rapid

adoption," stated Larry Jasinski, Chief Executive Officer of ReWalk.

"In November 2018, we submitted an application for CE

clearance and anticipate being able to launch ReStore mid-year. In the U.S., we are working to finalize our 510(k) submission to

the FDA and, if cleared, could have a product on the market before the end of the third quarter of 2019. To support our efforts,

we secured additional funding and will continue to manage our cash position. Our goal is to achieve a significant reduction in

operating expenses in 2019 compared to 2018 as we complete the regulatory and key development milestones related to the ReStore

launch, which we believe will reduce our burn rate in order to establish a path to break even," concluded Jasinski.

Fourth Quarter and Full Year

2018 Financial Results

Total revenue was $1.6 million for

the fourth quarter of 2018, compared to $1.5 million during the prior year quarter. 19 ReWalk systems were placed during the fourth

quarter of 2018, compared to 23 systems in the prior year period. Four systems were placed in the U.S. and 15 were placed in Europe.

Gross margin was 38.9% during the fourth

quarter of 2018, compared to 39.8% in the fourth quarter of 2017, primarily attributable to a one-time inventory write-off. Full

year 2018 gross margin was 43.2%, compared to 40.0% in 2017, reflecting our commitment to managing our operations.

Total operating expenses in the fourth

quarter of 2018 were $4.6 million, compared to $6.2 million in the prior year period. Total operating expenses for the full year

2018 were $22.0 million, compared to $25.1 million in 2017.

Operating cash flow usage was reduced

to $14.8 million in 2018, compared to $22.5 million in 2017, primarily due to working capital improvements and reduced operating

Net loss was $5.0 million for the fourth

quarter of 2018, compared to a net loss of $6.2 million in the fourth quarter of 2017. 2018 net loss was $21.7 million, compared

to 2017 net loss of $24.7 million.

Non-GAAP net loss for the fourth quarter

was $3.8 million, compared with a non-GAAP net loss of $4.9 million in the fourth quarter of 2017. 2018 Non-GAAP net loss was $17.6

million, compared to Non-GAAP 2017 net loss of $20.0 million. A reconciliation of net loss to non-GAAP net loss is included at

the end of this press release.

As of December 31, 2018, ReWalk had

$9.5 million in cash on its balance sheet and $8.7 million in short and long term debt.

ReWalk management will host its fourth

quarter 2018 conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 1095818.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation

and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel and the United States.

Forward-Looking Statements

In addition to historical information, this press release contains

forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the

U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include

projections regarding ReWalk's future performance and, in some cases, may be identified by words like "anticipate,"

"assume," "believe," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"future," "will," "should," "would," "seek" and similar terms or phrases.

The forward-looking statements contained in this press release are based on management's current expectations, which are

subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's

control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking

statements include, among others: ReWalk's ability to secure capital from its equity and debt financings in light of limitations

under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings

may dilute ReWalk's shareholders or restrict its business; ReWalk's ability to regain compliance with the continued

listing requirements of the Nasdaq Capital Market and the risk that its ordinary shares will be delisted if it cannot do so; ReWalk's

expectations regarding future growth, including its ability to increase sales in its existing geographic markets, and to expand

to new markets and achieve its planned expense reductions; the conclusion of ReWalk's management and the opinion of ReWalk's

auditors in that there are substantial doubts as to ReWalk's ability to continue as a going concern; ReWalk's ability

to maintain and grow its reputation and the market acceptance of its products; ReWalk's ability to achieve reimbursement

from third-party payors for its products; ReWalk's limited operating history and its ability to leverage our sales, marketing

and training infrastructure; ReWalk's expectations as to its clinical research program and clinical results; ReWalk's

ability to improve its products and develop new products; ReWalk's ability to repay its secured indebtedness; the outcome

of ongoing shareholder class action litigation relating to ReWalk's initial public offering; ReWalk's compliance with

medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events

on ReWalk's ability to market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's

expectations as to the results of, and the Food and Drug Administration's potential regulatory developments with respect

to, ReWalk's mandatory post-market 522 surveillance study and ReWalk's 510k submission for the ReStore for stroke patients;

ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual

property rights of others; the risk of a cybersecurity attack or breach of our IT systems significantly disrupting our business

operations; the risk that the remaining Timwell Corporation Limited ("Timwell") issuances will fail to close and the

China joint venture will not form, and the resulting effect on ReWalk's liquidity and financial condition; the risk of substantial

dilution resulting from additional issuances, if any, to Timwell; the significant voting power and de facto voting control Timwell

may acquire upon additional issuances, if any; ReWalk's ability to use effectively the proceeds of offerings of securities;

ReWalk's ability to maintain relationships with existing customers and develop relationships with new customers; the impact

of the market price of ReWalk's ordinary shares on the determination of whether ReWalk is a passive foreign investment company;

and other factors discussed under the heading "Risk Factors" in ReWalk's Annual Report on Form 10-K for the fiscal

year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission (the "SEC") and other documents

subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the

date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may

emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes

no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of